TScan Therapeutics Q4 net loss $23M; cash $152.4M; FDA clears TSC-102 INDs; plans Phase 3 trial Q2 2026

TScan Therapeutics, Inc.

Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.
Cash and equivalents $152.4M as of Dec 31, 2025; funds operations into H2 2027.
FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 for heme malignancies post-HCT.
Enrollment completed in Cohort C of ALLOHA heme trial with commercial-ready manufacturing; initial data due Q2 2026.
Discontinued solid tumor PLEXI-T trial; advancing in vivo TCR-T engineering and autoimmunity programs.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TScan Therapeutics, Inc. reported for the fourth quarter and fiscal year ended December 31, 2025 results: revenue $2.6 million.

Period: for the fourth quarter and fiscal year ended December 31, 2025
Revenue: $2.6 million
Result: reported results

Exact text from the filing

sharing preclinical proof-of-concept data for its therapeutic approach in the second half of 2026. Financial Results Revenue: Revenue for the fourth quarter of 2025 was $2.6 million, compared to $0.7 million for the fourth quarter of 2024, and $10.3 million for the full-year 2025, compared to $2.8 million for the full-year 2024. The increase in both periods

View on SEC.gov

Browse all earnings releases →

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-089871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.